Advanced search
Publication Cover
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Volume 20, 2019 - Issue 3-4
Submit an article Journal homepage
208
Views
1
CrossRef citations to date
0
Altmetric
Letter to the Editor

Edaravone administration in pivotal clinical Study 19

Angela GengeDepartment of Neurology, Clinical Research Unit, Montreal Neurological Institute, McGill University, Montreal, QC, Canada, Correspondence[email protected]
View further author information
&
Benjamin BrooksAtrium Health Neurosciences Institute, University of North Carolina School of Medicine, Charlotte, NC, USAView further author information
Pages 298-299 | Received 07 Jan 2019, Accepted 03 Feb 2019, Published online: 13 May 2019

References

  • Turnbull J. Is edaravone harmful? (A placebo is not a control). Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:477–482.
  • Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well-defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505–12.
  • Radicava® (edaravone injection) [package insert]. Jersey City, NJ: Mitsubishi Tanabe Pharma Corporation; August 2017.
  • Proudfoot M, Jones A, Talbot K, Al-Chalabi A, Turner MR. The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:414–25.
  • Fournier CN, Schoenfeld D, Berry JD, Cudkowicz ME, Chan J, Quinn C, et al. An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:242–9.
  • Kalin A, Medina-Paraiso E, Ishizaki K, Kim A, Zhang Y, Saita T, et al. A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:71–9.
  • Center for Drug Evaluation and Research (CDER). Radicava (edaravone) injection–NDA review documents 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209176Orig1s000TOC.cfm. Accessed December 11, 2018.
  • Bower L, Ji M, Apple S, Hoang M, Tran L, Hahn B, et al. Summary of the US safety data for Radicava® (edaravone): findings from the postmarketing pharmacovigilance. Presented at the 29th International Symposium on ALS/MND, Glasgow, Scotland, UK, 7–9 December 2018. Abstract CMS-11.
  • Baranovsky T, McAnanama G, Agnese W, Martin M. Radicava® (edaravone) for amyotrophic lateral sclerosis: US experience at 1 year after launch. Presented at the 29th International Symposium on ALS/MND, Glasgow, Scotland, UK, 7–9 December 2018. Abstract CMS-17.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.